Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Bought by ARK Investment Management LLC

ARK Investment Management LLC raised its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 9.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 198,606,619 shares of the company’s stock after buying an additional 16,414,434 shares during the quarter. Ginkgo Bioworks comprises about 2.0% of ARK Investment Management LLC’s portfolio, making the stock its 18th biggest holding. ARK Investment Management LLC owned about 9.38% of Ginkgo Bioworks worth $335,645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of DNA. Creative Planning acquired a new stake in shares of Ginkgo Bioworks during the fourth quarter worth about $25,000. Silverlake Wealth Management LLC acquired a new stake in shares of Ginkgo Bioworks during the fourth quarter worth about $25,000. Private Advisor Group LLC acquired a new stake in shares of Ginkgo Bioworks during the first quarter worth about $26,000. Aspen Grove Capital LLC acquired a new stake in shares of Ginkgo Bioworks during the first quarter worth about $27,000. Finally, American International Group Inc. lifted its position in shares of Ginkgo Bioworks by 56.8% during the second quarter. American International Group Inc. now owns 15,031 shares of the company’s stock worth $28,000 after purchasing an additional 5,445 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Trading Up 2.3 %

Shares of Ginkgo Bioworks stock opened at $1.10 on Thursday. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $1.03 and a 52 week high of $2.55. The firm’s 50 day moving average is $1.27 and its two-hundred day moving average is $1.47.

Ginkgo Bioworks (NYSE:DNA) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $34.76 million during the quarter, compared to analysts’ expectations of $40.37 million. Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The business’s revenue for the quarter was down 64.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) earnings per share. On average, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.32 EPS for the current year.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Jason R. Kelly sold 100,000 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $1.54, for a total value of $154,000.00. Following the completion of the sale, the insider now directly owns 3,994,680 shares of the company’s stock, valued at $6,151,807.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Mark E. Dmytruk sold 39,569 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total value of $47,878.49. Following the completion of the sale, the insider now directly owns 761,737 shares of the company’s stock, valued at $921,701.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jason R. Kelly sold 100,000 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $1.54, for a total value of $154,000.00. Following the completion of the sale, the insider now directly owns 3,994,680 shares of the company’s stock, valued at $6,151,807.20. The disclosure for this sale can be found here. 15.05% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. The Goldman Sachs Group reduced their price target on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating on the stock in a research report on Monday, January 22nd. TD Cowen cut their target price on shares of Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Ginkgo Bioworks presently has a consensus rating of “Hold” and an average price target of $2.20.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.